Inactivation of dap12 in pmn inhibits trem1-mediated activation in rheumatoid arthritis

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Chen, Xianghong ^a   Eksioglu, Erika A ^a   Carter, John D ^b   Fortenbery, Nicole ^b   Donatelli, Sarah S ^b   Zhou, Junmin ^c   Liu, Jinhong ^b   Yang, Lili ^a   Gilvary, Danielle ^c   Djeu, Julie ^b   Wei, Sheng ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE SYK; RANTES; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TREM1 PROTEIN, HUMAN; TYROBP PROTEIN, HUMAN;

ARTICLE; CELL ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DAP12 GENE; ENZYME ACTIVATION; GENE ACTIVATION; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; INFLAMMATORY CELL; INNATE IMMUNITY; INTRACELLULAR SIGNALING; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PATHOGENESIS; POLYMORPHONUCLEAR CELL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; TREM1 GENE; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; NEUTROPHIL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; NEUTROPHILS; RECEPTORS, IMMUNOLOGIC;

EID: 84922327075     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115116     Document Type: Article

References (53)

1. Goldring SR, Gravallese EM (2000) Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 12: 195-199. doi: 10.1097/00002281-200005000-00006
2. Walsh NC, Crotti TN, Goldring SR, Gravallese EM (2005) Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208: 228-251. doi: 10.1111/j.0105-2896.2005.00338.x
3. Gierut A, Perlman H, Pope RM (2010) Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am 36: 271-296. doi: 10.1016/j.rdc.2010.03.004
4. Nathan C (2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6: 173-182. doi: 10.1038/nri1785
5. Ulich TR, Dakay EB, Williams JH, Ni RX (1986) In vivo induction of neutrophilia, lymphopenia, and diminution of neutrophil adhesion by stable analogs of prostaglandins E1, E2, and F2 alpha. Am J Pathol 124: 53-58
6. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23: 225-274. doi: 10.1146/annurev.immunol. 23.021704.115526
7. Ravetch JV, Lanier LL (2000) Immune inhibitory receptors. Science 290: 84-89. doi: 10.1126/science. 290.5489.84
8. Crotti TN, Dharmapatni AA, Alias E, Zannettino AC, Smith MD, et al. (2012) The immunoreceptor tyrosine-based activation motif (ITAM)-related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther 14: R245. doi: 10.1186/ar4088
9. Molad Y, Pokroy-Shapira E, Carmon V (2013) CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immun 19: 623-630. doi: 10.1177/1753425913476970
10. Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21: 38-46. doi: 10.1016/j.coi.2009.01.009
11. Derive M, Massin F, Gibot S (2010) Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases. Self Nonself 1: 225-230. doi: 10.4161/self.1.3.12891
12. Klesney-Tait J, Turnbull IR, Colonna M (2006) The TREM receptor family and signal integration. Nat Immunol 7: 1266-1273. doi: 10.1038/ni1411
13. Tessarz AS, Cerwenka A (2008) The TREM-1/DAP12 pathway. Immunol Lett 116: 111-116. doi: 10. 1016/j.imlet.2007.11.021
14. Sharif O, Knapp S (2008) From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213: 701-713. doi: 10.1016/j.imbio.2008.07.008
15. Collins CE, La DT, Yang HT, Massin F, Gibot S, et al. (2009) Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis 68: 1768-1774. doi: 10.1136/ard.2008.089557
16. Kuai J, Gregory B, Hill A, Pittman DD, Feldman JL, et al. (2009) TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford) 48: 1352-1358. doi: 10.1093/rheumatology/kep235
17. Murakami Y, Akahoshi T, Aoki N, Toyomoto M, Miyasaka N, et al. (2009) Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis Rheum 60: 1615-1623. doi: 10.1002/art.24554
18. Schenk M, Bouchon A, Seibold F, Mueller C (2007) TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest 117: 3097-3106. doi: 10.1172/JCI30602
19. Wang DY, Qin RY, Liu ZR, Gupta MK, Chang Q (2004) Expression of TREM-1 mRNA in acute pancreatitis. World J Gastroenterol 10: 2744-2746
20. Kasama T, Miwa Y, Isozaki T, Odai T, Adachi M, et al. (2005) Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy 4: 273-279. doi: 10.2174/1568010054022114
21. Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545. doi: 10.1172/JCI36389
22. Chen X, Bai F, Sokol L, Zhou J, Ren A, et al. (2009) A critical role for DAP10 and DAP12 in CD8+ T cellmediated tissue damage in large granular lymphocyte leukemia. Blood 113: 3226-3234. doi: 10.1182/blood-2008-07-168245
23. Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, et al. (2013) Induction of myelodysplasia by myeloidderived suppressor cells. J Clin Invest. doi: 10.1172/JCI67580
24. Kasama T, Kobayashi K, Yajima N, Shiozawa F, Yoda Y, et al. (2000) Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA). Clin Exp Immunol 121: 533-538. doi: 10.1046/j.1365-2249.2000.01272.x
25. Burmester GR, Feist E, Dorner T (2014) Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 10: 77-88. doi: 10.1038/nrrheum.2013.168
26. Rankin JA (2004) Biological mediators of acute inflammation. AACN Clin Issues 15: 3-17. doi: 10. 1097/00044067-200401000-00002
27. Cope AP (2003) Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis. Rheumatology (Oxford) 42: 716-731. doi: 10.1093/rheumatology/keg262
28. Tsao NW, Bansback NJ, Shojania K, Marra CA (2012) The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Pract Res Clin Rheumatol 26: 659-676. doi: 10.1016/j.berh.2012.07.012
29. Feldmann M, Maini RN (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9: 1245-1250
30. Peppel K, Crawford D, Beutler B (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174: 1483-1489. doi: 10.1084/jem.174. 6.1483
31. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, et al. (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70: 266-271. doi: 10.1136/ard.2010.132134
32. Simard JF, Arkema EV, Sundstrom A, Geborek P, Saxne T, et al. (2011) Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford) 50: 204-213. doi: 10.1093/rheumatology/keq326
33. Rommel C, Camps M, Ji H (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7: 191-201. doi: 10.1038/nri2036
34. Bouchon A, Facchetti F, Weigand MA, Colonna M (2001) TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410: 1103-1107. doi: 10.1038/35074114
35. Bleharski JR, Kiessler V, Buonsanti C, Sieling PA, Stenger S, et al. (2003) A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J Immunol 170: 3812-3818. doi: 10.4049/jimmunol.170.7.3812
36. Bouchon A, Dietrich J, Colonna M (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 164: 4991-4995. doi: 10.4049/jimmunol.164.10.4991
37. Ornatowska M, Azim AC, Wang X, Christman JW, Xiao L, et al. (2007) Functional genomics of silencing TREM-1 on TLR4 signaling in macrophages. Am J Physiol Lung Cell Mol Physiol 293: L1377-1384. doi: 10.1152/ajplung.00140.2007
38. Gibot S, Kolopp-Sarda MN, Bene MC, Bollaert PE, Lozniewski A, et al. (2004) A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 200: 1419-1426. doi: 10.1084/jem.20040708
39. Gibot S, Alauzet C, Massin F, Sennoune N, Faure GC, et al. (2006) Modulation of the triggering receptor expressed on myeloid cells-1 pathway during pneumonia in rats. J Infect Dis 194: 975-983. doi: 10. 1086/506950
40. Wiersinga WJ, Veer C, Wieland CW, Gibot S, Hooibrink B, et al. (2007) Expression profile and function of triggering receptor expressed on myeloid cells-1 during melioidosis. J Infect Dis 196: 1707-1716. doi: 10.1086/522141
41. Kim TH, Choi SJ, Lee YH, Song GG, Ji JD (2012) Soluble triggering receptor expressed on myeloid cells-1 as a new therapeutic molecule in rheumatoid arthritis. Med Hypotheses 78: 270-272. doi: 10. 1016/j.mehy.2011.10.042
42. Humphrey MB, Daws MR, Spusta SC, Niemi EC, Torchia JA, et al. (2006) TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res 21: 237-245. doi: 10.1359/JBMR.051016
43. Bouchon A, Hernandez-Munain C, Cella M, Colonna M (2001) A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 194: 1111-1122. doi: 10.1084/jem.194.8.1111
44. Daws MR, Lanier LL, Seaman WE, Ryan JC (2001) Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol 31: 783-791. doi: 10.1002/1521-4141 (200103)31:3%3C783::AID-IMMU783%3E3.0.CO;2-U
45. Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, et al. (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 177: 2051-2055. doi: 10.4049/jimmunol.177.4.2051
46. Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, et al. (2003) DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 198: 669-675. doi: 10. 1084/jem.20030027
47. Joyce-Shaikh B, Bigler ME, Chao CC, Murphy EE, Blumenschein WM, et al. (2010) Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis. J Exp Med 207: 579-589. doi: 10.1084/jem.20090516
48. Chen DY, Yao L, Chen YM, Lin CC, Huang KC, et al. (2014) A potential role of myeloid DAP12-associating lectin (MDL)-1 in the regulation of inflammation in rheumatoid arthritis patients. PLoS One 9: e86105. doi: 10.1371/journal.pone.0086105
49. Cheung R, Shen F, Phillips JH, McGeachy MJ, Cua DJ, et al. (2011) Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice. J Clin Invest 121: 4446-4461. doi: 10.1172/JCI57682
50. O'Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368: 161-170. doi: 10.1056/NEJMra1202117
51. Feist E, Burmester GR (2013) Small molecules targeting JAKs-a new approach in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 52: 1352-1357. doi: 10.1093/rheumatology/kes417
52. Bajpai M, Chopra P, Dastidar SG, Ray A (2008) Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin Investig Drugs 17: 641-659. doi: 10.1517/13543784. 17.5.641
53. Lindstrom TM, RobinsonWH (2010) A multitude of kinases-which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin North Am 36: 367-383. doi: 10.1016/j.rdc.2010.02.005